PVCT..47/.48..there are a lot of facets to this play. I think the price is way to low:
-first-look at the prices in this financing relative to price when it was done a few days ago...investors paid over mkt..one of the keys here is that there are only 14m out,no pref... a very low sh count for a bio company moving now into revenue and with a broad patent portfolio:
+++Item 3.02. Unregistered Sales of Equity Securities.
On November 16, 2004, Provectus Pharmaceuticals, Inc. completed a private placement transaction with 14 accredited investors, pursuant to which we sold 556,832 shares of our common stock at a purchase price of $0.75 per share, for an aggregate purchase price of $417,624.25 pursuant to Securities Purchase Agreements with each investor. In connection with the sale of the common stock, we also issued warrants (the "Warrants") to the investors to purchase up to 835,249 shares of our common stock at an exercise price of $1.00 per share. We paid $41,762.43 to Venture Catalyst, LLC, 170 East 77th Street, Apt. 10F, New York, NY 10021 as placement agent for this transaction. The form of Securities Purchase Agreement entered into by each of the investors and the form of Warrant issued to the investors is attached hereto as Exhibit 4.1 and 4.2.
+++They have just placed this new qtr, not in past numbers yet, Pure-ific as thousands of stores-markup on this stuff is stiff-revenue will begin:
biz.yahoo.com
+++Their cancer drug has rec'd an IND from the FDA:
biz.yahoo.com
+++This letter to shareholders came out before much of the above took place:
biz.yahoo.com
+++They hold a broad, formidable patent portfolio in areas of oncology, dematology and anti-bacterial:
Intellectual Property
Patents
We hold a number of U.S. patents covering the technologies we have
developed and are continuing to develop for the production of prescription
drugs, medical devices and OTC pharmaceuticals, including those identified in
the following table:
U.S. Patent No. Title Issue Date Expiration Date
--------------- ----- ---------- ---------------
5,829,448 Method for improved selectivity in November 3, 1998 October 30, 2016
photo-activation of molecular agents
5,832,931 Method for improved selectivity in November 10, 1998 October 30, 2016
photo-activation and detection of
molecular diagnostic agents
5,998,597 Method for improved selectivity in December 7, 1999 October 30, 2016
photo-activation of molecular agents
7
U.S. Patent No. Title Issue Date Expiration Date
--------------- ----- ---------- ---------------
6,042,603 Method for improved selectivity in March 28, 2000 October 30, 2016
photo-activation of molecular agents
6,331,286 Methods for high energy phototherapeutics December 18, 2001 December 21, 2018
6,451,597 Method for enhanced protein stabilization September 17, 2002 April 6, 2020
and for production of cell lines useful
for production of such stabilized proteins
6,468,777 Method for enhanced protein stabilization October 22, 2002 April 6, 2020
and for production of cell lines useful
for production of such stabilized proteins
6,493,570 Method for improved imaging and December 10, 2002 December 10, 2019
photodynamic therapy
6,495,360 Method for enhanced protein stabilization December 17, 2002 April 6, 2020
and for production of cell lines useful
for production of such stabilized proteins
6,519,076 Methods and apparatus for optical imaging February 11, 2003 October 30, 2016
6,525,862 Methods and apparatus for optical imaging February 25, 2003 October 30, 2016
6,541,223 Method for enhanced protein stabilization April 1, 2003 April 6, 2020
and for production of cell lines useful
for production of such stabilized proteins
We continue to pursue patent applications on numerous other developments we
believe to be patentable. We consider our issued patents, our pending patent
applications and any patentable inventions which we may develop to be extremely
valuable assets of our business.
+++ i think we will continue to hear more from these guys and the price here at .50 offer is ridiculous. Period. I own a LOT> |
